Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant trastuzumab-based chemotherapy with or without bevacizumab for HER2-positive high-risk breast cancer
2007-005182-35Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, trastuzumab, docetaxel, carboplatin, fluorouracil in breast cancer, sponsored by Roche. Started Mar 2008; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-005182-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005182-35.